CANCER IMMUNOPREVENTION SERIES

1067 Cancer Immunoprevention: A New Approach to Intercept Cancer Early
Asad Umar

1072 Cancer Immunoprevention—The Next Frontier
Marie-Anne D. Smit, Elizabeth M. Jaffee, and Eric R. Lutz

REVIEW

1081 Targeting Apoptosis Pathways in Cancer and Perspectives with Natural Compounds from Mother Nature
Faya M. Millimouno, Jia Dong, Liu Yang, Jiang Li, and Xiaomeng Li

PERSPECTIVE

1108 Human Fecal Microbiome–Based Biomarkers for Colorectal Cancer
Vilvapathy Narayanan, Maikel P. Peppelenbosch, and Sergey R. Konstantinov
See related article, p. 1112

RESEARCH ARTICLES

1112 The Human Gut Microbiome as a Screening Tool for Colorectal Cancer
Joseph P. Zackular, Mary A.M. Rogers, Mack T. Ruffin IV, and Patrick D. Schloss
See related article, p. 1108

1122 C-reactive Protein and Risk of Colorectal Adenomas or Serrated Polyps: A Prospective Study
Seth D. Crockett, Leila A. Mott, Elizabeth L. Barry, Jane C. Figueiredo, Carol A. Burke, Gwen J. Baxter, Robert S. Sandler, and John A. Baron

1128 Folate and Vitamin B12 May Play a Critical Role in Lowering the HPV 16 Methylation–Associated Risk of Developing Higher Grades of CIN
Chandrika J. Piyathilake, Maurizio Macaluso, Michelle M. Chambers, Suguna Badiga, Nuzhat R. Siddiqui, Walter C. Bell, Jeffrey C. Edberg, Edward E. Partridge, Ronald D. Alvarez, and Gary L. Johanning

1138 Omega-3 Fatty Acid Is a Potential Preventive Agent for Recurrent Colon Cancer

1149 Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function
Jing Pan, Qi Zhang, Qian Liu, Steven M. Komas, Balaraman Kalyanaraman, Ronald A. Lubet, Yian Wang, and Ming You

1160 The Concentrations of EGFR, LRG1, ITIH4, and F5 in Serum Correlate with the Number of Colonic Adenomas in Apc<sup>min/+</sup> Rats
Melanie M. Ivancic, Amy A. Irving, Kelli G. Jonakin, William F. Dove, and Michael R. Sussman

LETTERS TO THE EDITOR

1170 PARP Inhibitors for Chemoprevention—Letter
Saswati N. Chand, Fernando F. Blanco, Masaya Jimbo, Theodore N. Tsangaris, Massimo Cristofanilli, Charles J. Yeo, Jordan M. Winter, Michael J. Pishvaian, and Jonathan R. Brody

1172 PARP Inhibitors for Chemoprevention—Reply
Ciric To, Michael B. Sporn, and Karen T. Liby

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

Dysregulation of Wnt/β-catenin pathway has been reported to play a pivotal role in the development and progression of colorectal cancer. β-catenin is a downstream component of the Wnt signaling pathway. In the absence of Wnt stimulation, the levels of cytoplasmic β-catenin are low since the phosphorylated β-catenin is ubiquitinated and constantly degraded in the proteasome. In recurrent colon cancer, the coordinated phosphorylation and destruction of β-catenin is disrupted resulting in its accumulation and translocation to the nucleus, where it activates the transcription of its target genes, cyclin D1 and c-myc. The figure depicts indirect immunofluorescence staining of parental HT-29 cells showing membranous and cytoplasmic localization of β-catenin (green). Counter staining was performed with DAPI (blue) ×100. See article by Vasudevan and colleagues (beginning on page 1138) for more information.